Donald P. Braun, Ph.D. joined Cancer Treatment Centers of America in 2006 as its Vice President of Clinical Research. In 2014 he was named Vice President of Translational Research and Chief Science Officer where he served until 2016. Prior to joining Cancer Treatment Centers of America, he was the Scientific Director ofthe Cancer Center and Professor of Medicine and Immunology at Rush Medical College in Chicago, and the Administrative Director of the Cancer Institute and a Professor of Surgery with tenure in the Basic Science Track at the Medical College of Ohio.
Dr. Braun received his undergraduate degree in Biology and Microbiology from the University of Illinois in Urbana, and his Ph.D. in Immunology and Microbiology from the University of Illinois at the Medical Center in Chicago. He has over 3 5 years of research experience in oncology, cancer immunology, cancer immunotherapy, and inflammatory diseases. He is the author of more than 120 published peer-reviewed manuscripts, 25 reviews and book chapters, and co-editor of a book on the role of prostaglandins and other COX 2 metabolites in cancer patient immunity and immunotherapy.
Dr. Braun has served as an advisor to numerous public agencies and private corporations concerned with cancer therapeutics and diagnostics. At the National Cancer Institute, Dr. Braun served as a member of the Experimental Therapeutics Study Section; the Small Business Innovation Grant Review Study Section; and the Experimental Therapy program for “Molecular Targets in Lung Cancer”. He served as a member of the Immunology and Immunotherapy Study Section of the American Cancer Society-National Division; as a Member of the Ohio Cancer Incidence Surveillance System; as a Member of the Biomedical Research Technology Transfer Commission for the State of Ohio; and as an advisor to the State of Arizona’s Disease Research Control Commission. Dr. Braun has also served as a consultant to numerous Pharmaceutical and Biotechnology Companies developing cancer treatments and diagnostics including: Pfizer Pharmaceuticals; Sterling Winthrop; Abbott Laboratories; Boehringer Mannheim; Serono Corporation; Lorus Therapeutics; RxKinetix Inc; Methapharm; EMDiagnostics; Biomira Inc; Centocor; and Merck KGA.
Dr. Braun’s latest endeavors include serving as a member of Board ofDirectors of Celsion Pharmaceuticals, a publically-traded company devoted to developing innovative treatments for cancer and as a member of the Medical Scientific Advisory Board of Mitra Biotechnology whose core technology seeks to develop predictive assays for cancer therapeutics.